 |
| Treating Childhood Asthma |
|
| Because asthma can't be cured, the goal of asthma treatment is to control symptoms and prevent attacks.
|
|
| When your child has an asthma attack, a couple of things happen in his or her lungs. One is constriction or narrowing of the airways, and the other is inflammation or swelling of the airways. To help with both problems, asthma medicines are broken into two general categories: rescue drugs, and long-term control drugs. Rescue drugs are typically used when asthma symptoms develop. Long-term control drugs help prevent the swelling caused by inflammation.1 Most asthma medicine is inhaled directly into the airways using various delivery systems: nebulizers, metered-dose inhalers, and dry powder inhalers. |
|
| The stepwise approach |
|
| A stepwise approach to treat asthma is recommended by the National Asthma Education and Prevention Program (NAEPP). What this means is that asthma medication should be increased only when necessary, and decreased whenever possible. The goal is to maintain control of asthma with the least amount of medication and the lowest risk of side effects.2 |
|
| With this goal in mind, your child's doctor will prescribe and adjust medicine based on the severity of your child's asthma. However, if you are not satisfied with either the level of asthma control or the severity of side effects from your child's current medicine, talk to his or her doctor. The physician may be able to prescribe another medication or adjust the dose to a level that controls your child's asthma without excessive side effects. |
|
| AccuNeb® (albuterol sulfate) Inhalation Solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). |
 |
| Important Safety Information |
|
| In a clinical trial with AccuNeb® Inhalation Solution 0.63 mg, AccuNeb® Inhalation Solution 1.25 mg, and placebo, the most commonly reported adverse events were asthma exacerbations (11.1%, 13%, 8.5%), otitis media (0.9%, 4.3%, 0%), allergic reaction (3.4%, 0.9%, 1.7%), gastroenteritis (3.4%, 0.9%, 0.9%), and flu syndrome (2.6%, 2.6%, 1.7%). |
|
| Like other beta-adrenergic agonists, AccuNeb® Inhalation Solution can produce paradoxical bronchospasm, which may be life-threatening. AccuNeb® Inhalation Solution should be used with caution in patients with cardiovascular disorders and patients being treated with epinephrine, oral sympathomimetics, beta-blockers, MAOIs, or tricyclic antidepressants. |
|
| Please see Patient Prescribing Information. |
|
|
|
|
|
|
 |
|
|
|
